HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raised the price target from $36 to $38.
July 24, 2023 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Syndax Pharmaceuticals' price target has been raised from $36 to $38 by HC Wainwright & Co., maintaining a 'Buy' rating.
The raised price target and reiterated 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Syndax Pharmaceuticals. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100